Home > Journals > Minerva Gastroenterology > Past Issues > Articles online first > Minerva Gastroenterology 2021 Apr 19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Gastroenterology 2021 Apr 19

DOI: 10.23736/S2724-5985.21.02911-9

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification

Francesco STALLA 1, Angelo ARMANDI 1, Chiara MARINONI 1, Sharmila FAGOONEE 2, Rinaldo PELLICANO 3, Gian Paolo CAVIGLIA 1

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Institute of Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Torino, Italy; 3 Division of Gastroenterology, Molinette Hospital - Città della Salute e della Scienza di Torino, Turin, Italy


PDF


Despite the availability of an effective vaccination, chronic hepatitis B virus (HBV) infection is still a major health concern worldwide. Chronic HBV infection can lead to fibrosis accumulation and overtime to cirrhosis, the principal risk factor for liver failure and hepatocellular carcinoma development. Liver biopsy is still considered the gold standard for fibrosis assessment, even though it is invasive and not exempt of complications. Overtime, several non-invasive methods for the detection of liver fibrosis have been developed and gradually introduced into clinical practice. However, their main limitation is the poor performance for the detection of intermediate stages of fibrosis. Finally, novel serological biomarkers, polygenic risk scores and imaging methods have been proposed in last years as novel promising tools to correctly identify the degree of liver fibrosis and to monitor liver disease progression. In this narrative review, we provide an overview on the novel non-invasive approaches for the evaluation of liver fibrosis and risk stratification of patients with chronic hepatitis B.


KEY WORDS: Biomarkers; HBV; Liver fibrosis

top of page